Glioblastoma preclinical models: Strengths and weaknesses
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2024-01 · 1879 (1) · 189059
DOI: 10.1016/j.bbcan.2023.189059 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024-01. Verfasst von Vasavi Pasupuleti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 169 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glioblastoma multiforme is a highly malignant brain tumor with significant intra- and intertumoral heterogeneity known for its aggressive nature and poor prognosis. The complex signaling cascade that regulates this heterogeneity makes targeted drug therapy ineffective. The development of an optimal preclinical model is crucial for the comprehension of molecular heterogeneity and enhancing therapeutic efficacy. The ideal model should establish a relationship between various oncogenes and their corresponding responses. This review presents an analysis of preclinical in vivo and in vitro models that have contributed to the advancement of knowledge in model development. The experimental designs utilized in vivo models consisting of both immunodeficient and immunocompetent mice induced with intracranial glioma. The transgenic model was generated using various techniques, like the viral vector delivery system, transposon system, Cre-LoxP model, and CRISPR-Cas9 approaches. The utilization of the patient-derived xenograft model in glioma research is valuable because it closely replicates the human glioma microenvironment, providing evidence of tumor heterogeneity. The utilization of in vitro techniques in the initial stages of research facilitated the comprehension of molecular interactions. However, these techniques are inadequate in reproducing the interactions between cells and extracellular matrix (ECM). As a result, bioengineered 3D-in vitro models, including spheroids, scaffolds, and brain organoids, were developed to cultivate glioma cells in a three-dimensional environment. These models have enabled researchers to understand the influence of ECM on the invasive nature of tumors. Collectively, these preclinical models effectively depict the molecular pathways and facilitate the evaluation of multiple molecules while tailoring drug therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, India.
- School of Pharmacy, Queen's University Belfast, 97 Lisburn Road, BT9 7BL, UK. Electronic address: L.Vora@qub.ac.uk.
- Department of Anatomy, Korea University College of Medicine, Moonsuk Medical Research Building, 516, 5th floor, 73 Inchon-ro, Seongbuk-gu, Seoul 12841, Republic of Korea.
- Department of Neurochemistry National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India.
- Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, India. Electronic address: dkkhatri10@gmail.com.
Zitieren
APA
Pasupuleti, V., Vora, L., Prasad, R., Nandakumar, D. N., & Khatri, D. K. (2024). Glioblastoma preclinical models: Strengths and weaknesses. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1879(1), 189059. https://doi.org/10.1016/j.bbcan.2023.189059
Vancouver
Pasupuleti V, Vora L, Prasad R, Nandakumar DN, Khatri DK. Glioblastoma preclinical models: Strengths and weaknesses. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2024;1879(1):189059. doi:10.1016/j.bbcan.2023.189059
BibTeX
@article{Pasupuleti2024,
author = {Pasupuleti, Vasavi and Vora, Lalitkumar and Prasad, Renuka and Nandakumar, D N and Khatri, Dharmendra Kumar},
title = {Glioblastoma preclinical models: Strengths and weaknesses},
journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
year = {2024},
volume = {1879},
number = {1},
pages = {189059},
doi = {10.1016/j.bbcan.2023.189059}
}
EUVIMED